Markets
Borrow
Earn
Invest
Private
Security
Newsroom
More
Log In
Sign Up
Markets
Market Overview
Indices and commodities.
Digital Credit
Bitcoin treasury preferreds.
AI Stocks
The artificial intelligence theme.
Bitcoin Treasuries
Companies holding bitcoin.
Economy
Sectors, global markets and rates.
Popular Portfolios
13F filings, smart money.
Borrow
Borrow
Borrow USDT or USDC against your BTC without giving it up.
ReFi
Switch your bitcoin-backed loan and pay less interest.
Earn
Carry Trade
Borrow, invest, keep the spread.
Stock Dividends
Dividends from tokenized equities.
Invest
Private
Security
Newsroom
More
Company
About Us
Our leadership team, mission, and investors.
Whitepaper
Vision, purpose, and architecture behind Roxom.
Legal
Terms, privacy, and disclosures.
Resources
Help Center
Guides, FAQs & support.
Rulebook
Trading logic, platform rules, and fundamentals.
API Docs
Connect, authenticate, and build with our API.
Status
Current platform health and incidents.
Chart
Financials
Earnings
News
About
Dividends
Insider
Filings
BTC
SATS
USD
1d
1w
1m
6m
YTD
1y
5y
All
Loading chart
1 BTC
=
- USD
BTC
SATS
Loading market data...
Chart
Financials
Earnings
News
About
Dividends
Insider
Filings
BTC
SATS
USD
1d
1w
1m
6m
YTD
1y
5y
All
Loading chart
AB
Acumen Pharmaceuticals, Inc. Common Stock
ABOS
Mkt Cap
$122.6M
Volume
396.10K
Next Earnings
November 11th
Chart
Financials
Earnings
News
About
Dividends
Insider
Filings
BTC
SATS
USD
1d
1w
1m
6m
YTD
1y
5y
All
Loading chart
AB
ABOS
AB
Acumen Pharmaceuticals, Inc. Common Stock
ABOS
News
·
Acumen Pharmaceuticals to Hold Virtual Investor Day on September 16, 2026
Mkt Cap
$120.8M
Volume
396.10K
Next Earnings
November 11th
Chart
Financials
Earnings
News
About
Insider
Filings
Acumen Pharmaceuticals to Hold Virtual Investor Day on September 16, 2026
Acumen Pharmaceuticals announced a virtual Investor Day scheduled for September 16, 2026, to discuss its clinical-stage pipeline. The company is advancing sabirnetug (ACU193), a monoclonal antibody targeting toxic amyloid beta oligomers for Alzheimer's disease treatment, with Phase 2 ALTITUDE-AD trial results expected in late 2026. Acumen is also exploring subcutaneous formulations and collaborating with JCR Pharmaceuticals on enhanced brain delivery technologies.
GlobeNewswire Inc. · Sep 10, 2026
Acumen Pharmaceuticals to Participate in Upcoming Investor Conferences
Acumen Pharmaceuticals announced that management will participate in two upcoming investor conferences in September 2026: the Cantor Global Healthcare Conference on September 9 and Citi's 2026 Biopharma Back to School Conference on September 10. The company is advancing its lead candidate sabirnetug (ACU193) in Phase 2 trials for early symptomatic Alzheimer's disease and expects to report topline results in late 2026.
GlobeNewswire Inc. · Sep 2, 2026
Acumen Pharmaceuticals Reports First Quarter 2026 Financial Results and Business Highlights
Acumen Pharmaceuticals reported Q1 2026 financial results with cash reserves of $128.4 million. The company expects topline results from its Phase 2 ALTITUDE-AD study investigating sabirnetug for early Alzheimer's disease in late 2026, and plans to file an IND for its lead EBD program candidate in mid-2027. R&D expenses decreased to $16.5 million from $25.3 million year-over-year due to reduced manufacturing and CRO costs following ALTITUDE-AD enrollment completion.
GlobeNewswire Inc. · May 12, 2026
Acumen Pharmaceuticals to Participate in the Bank of America Securities 2026 Health Care Conference
Acumen Pharmaceuticals announced that management will participate in a fireside chat at the Bank of America Securities 2026 Health Care Conference on May 14, 2026. The company is advancing its lead candidate sabirnetug (ACU193), a monoclonal antibody targeting toxic amyloid beta oligomers, in its Phase 2 ALTITUDE-AD trial for early symptomatic Alzheimer's disease, with topline results expected in late 2026.
GlobeNewswire Inc. · May 7, 2026
Acumen Pharmaceuticals to Report First Quarter Financial Results on May 12, 2026
Acumen Pharmaceuticals announced it will report first quarter 2026 financial results on May 12, 2026, with a conference call and webcast at 8:00 a.m. ET. The clinical-stage biopharmaceutical company is advancing sabirnetug (ACU193), a monoclonal antibody targeting amyloid beta oligomers for Alzheimer's disease treatment, with topline results from the Phase 2 ALTITUDE-AD trial expected in late 2026.
GlobeNewswire Inc. · May 5, 2026
Acumen Pharmaceuticals to Report Fourth Quarter and Year-End 2025 Financial Results on March 26, 2026
Acumen Pharmaceuticals announced it will report Q4 and year-end 2025 financial results on March 26, 2026, with a conference call at 8:00 a.m. ET. The clinical-stage biopharmaceutical company is advancing sabirnetug (ACU193), a monoclonal antibody targeting amyloid beta oligomers for Alzheimer's disease treatment, currently in Phase 2 trials.
GlobeNewswire Inc. · Mar 19, 2026
Acumen Pharmaceuticals to Participate in the Stifel 2026 Virtual CNS Forum
Acumen Pharmaceuticals announced that management will participate in a fireside chat at the Stifel 2026 Virtual CNS Forum on March 18, 2026. The clinical-stage biopharmaceutical company is advancing sabirnetug (ACU193), a monoclonal antibody targeting toxic soluble amyloid beta oligomers for Alzheimer's disease treatment, currently in Phase 2 trials following positive Phase 1 results.
GlobeNewswire Inc. · Mar 10, 2026
Acumen Pharmaceuticals to Report Third Quarter 2025 Financial Results on November 12, 2025
Acumen Pharmaceuticals will report its Q3 2025 financial results on November 12, 2025, hosting a conference call and webcast to provide a business and financial update. The company is developing a novel therapeutic targeting toxic amyloid beta oligomers for Alzheimer's disease treatment.
GlobeNewswire Inc. · Nov 5, 2025
Acumen Pharmaceuticals to Participate in Upcoming Investor Conferences
Acumen Pharmaceuticals will participate in two upcoming investor conferences in September 2025, presenting its ongoing research into Alzheimer's disease treatment using sabirnetug (ACU193), a monoclonal antibody targeting toxic amyloid beta oligomers.
GlobeNewswire Inc. · Aug 26, 2025
Acumen Pharmaceuticals to Report Second Quarter 2025 Financial Results on August 12, 2025
Acumen Pharmaceuticals will report Q2 2025 financial results on August 12, 2025, and host a conference call to provide a business and financial update, focusing on their Alzheimer's disease therapeutic candidate sabirnetug.
GlobeNewswire Inc. · Aug 5, 2025
Holdings
Open Orders (0)
Positions (0)
Order History
Dividends
Transfers
Log In
to start trading
AB
ABOS
Acumen Pharmaceuticals, Inc. Common Stock
Buy
Sell
Market
Limit
Soon
ABOS
25%
50%
75%
Max
Pay with
—
Start Trading
Available Balance
0.00
Your Position
You don't own any ABOS yet.
Related Tickers
Earnings